PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16940805-5	2006	Co-administration of tumor necrosis factor-alpha in the isolated limb perfusion with melphalan induced a six-fold enhanced drug accumulation of melphalan in the tumor compared with isolated limb perfusion with melphalan alone.	Melphalan	85-94	tumor necrosis factor	Rattus norvegicus	21-48	
16940805-5	2006	Co-administration of tumor necrosis factor-alpha in the isolated limb perfusion with melphalan induced a six-fold enhanced drug accumulation of melphalan in the tumor compared with isolated limb perfusion with melphalan alone.	Melphalan	144-153	tumor necrosis factor	Rattus norvegicus	21-48	
16940805-5	2006	Co-administration of tumor necrosis factor-alpha in the isolated limb perfusion with melphalan induced a six-fold enhanced drug accumulation of melphalan in the tumor compared with isolated limb perfusion with melphalan alone.	Melphalan	144-153	tumor necrosis factor	Rattus norvegicus	21-48	
15899822-8	2005	Additionally, increased levels of TNF mRNA were found in tumors treated with IL-2 and IL-2 plus melphalan.	Melphalan	96-105	tumor necrosis factor	Rattus norvegicus	34-37	
10389992-7	1999	Synergy between TNF and melphalan was lost at a dose of TNF below 10 microg in 5 ml perfusate.	Melphalan	24-33	tumor necrosis factor	Rattus norvegicus	56-59	
12094545-3	2002	Here, we determined the cytotoxic effect of TNF-alpha on several tumor cell lines in vitro in combination with doxorubicin (cell-cycle dependent) or melphalan (cell-cycle independent), and its effect on cell-cycle progression.	Melphalan	149-158	tumor necrosis factor	Rattus norvegicus	44-53	
10956394-1	2000	It has previously been demonstrated in the setting of an isolated limb perfusion that application of high-dose TNF-alpha in combination with chemotherapy (melphalan, doxorubicin) results in strong synergistic antitumor effects in both the clinical and preclinical settings.	Melphalan	155-164	tumor necrosis factor	Rattus norvegicus	111-120	
10916754-9	2000	When TNF was added to melphalan, a dramatic anti-tumor effect was observed.	Melphalan	22-31	tumor necrosis factor	Rattus norvegicus	5-8	
8038591-11	1994	We conclude that high-dose rTNF-alpha associated with melphalan in isolation perfusion is the therapy of choice for in-transit melanoma metastases.	Melphalan	54-63	tumor necrosis factor	Rattus norvegicus	27-37	
9733636-12	1998	CONCLUSION: TBI and the associated reduction in WBC count decreased the tumor response by TNFalpha and melphalan significantly and abrogated the immediate response of skin necrosis at the tumor site, as found in rats treated with TNFalpha and melphalan without TBI.	Melphalan	103-112	tumor necrosis factor	Rattus norvegicus	230-238	
8980389-15	1996	In conclusion, our findings suggest that the enhanced anti-tumour effect after the combination of TNF-alpha with melphalan results from potentiation of the TNF-alpha-induced vascular changes accompanied by increased vascular permeability and platelet aggregation.	Melphalan	113-122	tumor necrosis factor	Rattus norvegicus	156-165